Alembic Pharmaceuticals Ltd logo

Alembic Pharmaceuticals Ltd

APLLTD NSE

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

AI Verdict: HOLD Confidence: 5%

Alembic Pharmaceuticals shows improving profitability with 28% TTM profit growth and healthy dividend payout of 35.7%, but weak 5-year sales CAGR of just 6% and low ROE of 12.7% limit upside conviction. With 55.56% of analysts rating it a Hold and the stock trading at 2.64x book value without commensurate returns, patience is warranted.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹15,377 Cr
Volatility
Moderate
P/E Ratio
22.48
EBITDA
₹1,051 Cr
Return on Equity
12.78%
Debt to Equity
0.18
Book Value
₹288.7
EPS
₹32.05
52W High
₹1,107.9
52W Low
₹635.8

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 35.7%

Weaknesses

5
  • Stock is trading at 2.70 times its book value
  • The company has delivered a poor sales growth of 6.37% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.7% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
9.39% ↗
Net Income Growth
-2.69% ↘
Cash Flow Change
-89.05% ↘
ROE
-12.21% ↘
ROCE
6.31% ↗
EBITDA Margin (Avg.)
-9.20% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk medium

Alembic Pharmaceuticals shows improving profitability with 28% TTM profit growth and healthy dividend payout of 35.7%, but weak 5-year sales CAGR of just 6% and low ROE of 12.7% limit upside conviction. With 55.56% of analysts rating it a Hold and the stock trading at 2.64x book value without commensurate returns, patience is warranted.

Bull Case 7
  • Strong profit acceleration with TTM compounded profit growth of 28%, indicating margin expansion and operational leverage
  • Consistent dividend payout ratio of 35.7% provides income cushion and signals management confidence in cash flows
  • 10-year compounded sales CAGR of 9% demonstrates long-term revenue sustainability in a defensive healthcare sector
  • 3-year compounded profit CAGR of 28% shows sustained earnings recovery after the post-COVID margin compression
  • PE ratio of 22x is reasonable for a pharma company delivering 28% profit growth, implying a PEG ratio below 1.0
  • Dividend yield of 1.47% is above the pharma sector median, offering downside protection in volatile markets
  • 3-year stock CAGR of 7% with accelerating earnings suggests potential re-rating if profit growth sustains
Bear Case 8
  • Poor 5-year sales CAGR of only 6.37% signals weak top-line momentum and limited pricing power
  • Low 3-year average ROE of 12.7% indicates suboptimal capital efficiency for a mid-cap pharma company
  • Stock trading at 2.64x book value is expensive given the modest ROE, destroying the value-investing thesis
  • Negative 5-year stock CAGR of -5% reflects sustained underperformance and poor shareholder wealth creation
  • 5-year compounded profit CAGR of -9% reveals that recent profit recovery is a rebound, not structural growth
  • Potential capitalization of interest costs raises concerns about true debt servicing burden and earnings quality
  • Low effective tax rate raises sustainability concerns — normalization could compress net margins going forward
  • Zero analyst sell ratings but 55.56% hold ratings suggest limited near-term catalysts for re-rating

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Positives 5
  • 45% stake in Canadian JV Jun 6

    Alembic signed a Shareholders' Agreement to acquire 45% equity in 17989377 Canada Inc., a joint venture to develop and market pharma products in Canada.

  • Binimetinib tentative approval, $260M market Jun 19

    Received tentative USFDA approval for Binimetinib Tablets targeting a US market worth $260 million, adding to its generics portfolio.

  • Larotrectinib with 180-day exclusivity Jun 11

    Tentative USFDA approval for Larotrectinib Capsules (25 mg, 100 mg) targeting $91 million market. As sole first applicant, Alembic may get 180 days of generic marketing exclusivity.

  • Tretinoin Cream final approval Jun 13

    Final USFDA approval for Tretinoin Cream USP 0.05% targeting a $76 million market. Company now holds 242 ANDA approvals.

  • Haloperidol Tablets final approval Jun 5

    Final USFDA approval for Haloperidol Tablets in multiple dosages targeting a projected US market of $27 million by FY26.

Neutral 5
  • Investor meets with major MFs Jun 19

    Alembic scheduled meetings with HDFC MF, Tata MF, DSP MF, and HDFC Life on June 22, 23, and 25, 2026 for business updates.

  • New independent director appointed Jun 18

    Sujit Jaysukh Bhayani appointed as Non-Executive Independent Director for five years effective June 18, 2026, subject to shareholder approval.

  • AGM and dividend record date set Jun 9

    16th AGM scheduled for August 5, 2026 via video conferencing. Record date for FY26 dividend fixed at July 29, 2026.

  • New Head-R&D (API) appointed Jun 3

    Tushar Mehta appointed Head-R&D (API) effective June 3, 2026, bringing over 24 years of experience in API research and development.

  • Senior management designation Jun 1

    Ramesh Juneja designated as Senior Management Personnel effective June 1, 2026, with over 30 years of pharma sales and marketing experience.

TL;DR: Alembic Pharmaceuticals is on a strong USFDA approval streak, securing multiple approvals in June targeting a combined addressable US market exceeding $450 million, with potential 180-day exclusivity on Larotrectinib. The Canadian JV adds geographic diversification. No visible headwinds in the current news cycle. The trend is clearly positive with expanding pipeline approvals and international expansion signaling continued growth momentum.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
1,406
1,486
1,595
1,631
1,517
1,562
1,648
1,693
1,770
1,711
1,910
1,876
1,848
Expenses
1,203
1,287
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,594
1,585
1,620
Operating Profit
204
199
208
266
260
237
239
260
271
281
316
292
228
OPM %
14%
13%
13%
16%
17%
15%
15%
15%
15%
16%
17%
16%
12%
Other Income
1
12
10
3
4
2
30
10
14
6
8
-27
2
Interest
14
14
16
15
11
13
19
22
25
24
24
23
23
Depreciation
74
66
68
69
69
69
71
70
69
74
76
80
89
PBT
116
130
135
185
183
157
180
178
192
190
224
162
119
Tax %
-31%
7%
-1%
2%
3%
14%
15%
23%
18%
19%
18%
18%
-70%
Net Profit
153
121
137
180
178
135
153
138
157
154
184
132
202
EPS in Rs
7.76
6.14
6.95
9.18
9.07
6.85
7.8
7.04
7.98
7.85
9.4
6.76
10.31
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
2,056
3,166
3,105
3,131
3,935
4,606
5,393
5,306
5,653
6,229
6,672
7,345
Expenses
1,653
2,159
2,490
2,488
3,061
3,383
3,913
4,432
4,970
5,296
5,664
6,226
Operating Profit
403
1,007
615
643
874
1,223
1,480
874
682
932
1,008
1,118
OPM %
20%
32%
20%
21%
22%
27%
27%
16%
12%
15%
15%
15%
Other Income
4
7
2
7
9
-39
87
56
-2
28
56
-12
Interest
4
5
5
3
18
27
16
18
50
56
79
94
Depreciation
44
72
83
105
115
157
183
287
275
273
279
319
PBT
359
936
529
541
749
1,000
1,368
625
355
632
707
694
Tax %
21%
23%
23%
22%
21%
20%
19%
17%
4%
3%
18%
3%
Net Profit
283
720
403
413
583
801
1,146
521
342
616
582
671
EPS in Rs
15.01
38.2
21.39
21.89
31
43.97
58.33
26.5
17.4
31.33
29.68
34.33
Div. Payout %
23%
9%
19%
18%
18%
23%
24%
38%
46%
35%
37%
35%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
38
38
38
38
38
38
39
39
39
39
39
39
Reserves
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
5,636
Borrowings
264
114
89
708
1,128
1,747
584
717
722
513
1,258
1,430
Other Liabilities
493
718
698
1,013
931
1,022
1,058
1,167
1,090
1,114
1,324
1,658
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Fixed Assets
547
708
799
993
1,158
1,552
1,788
1,798
2,398
2,547
2,524
3,130
CWIP
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
634
Investments
2
87
50
42
49
18
236
118
96
93
127
141
Other Assets
1,009
1,541
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,281
4,285
4,858
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
172
948
329
312
812
449
1,463
552
724
803
88
783
Investing
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
-506
Financing
87
-224
-129
503
59
155
-597
-217
-262
-438
444
-164
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
113
Free Cash Flow
-52
647
348
-495
49
-285
804
128
282
487
-466
290
CFO/OP
60
114
73
70
112
56
115
77
115
88
16
79
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
40
40
61
45
69
24
56
68
60
77
73
Inventory Days
196
266
269
302
356
417
431
406
315
350
466
462
Days Payable
166
264
213
313
237
220
194
178
145
157
179
154
Cash Conversion Cycle
94
42
96
51
164
266
261
283
237
253
363
381
Working Capital Days
32
36
61
69
24
50
73
74
77
88
87
88
ROCE %
38%
66%
29%
22%
23%
24%
26%
11%
7%
13%
13%
13%

Shareholding Pattern

As of Mar 2026
Promoters 69.74%
DIIs 16.18%
Public 6.86%
FIIs 4.25%
Others 2.96%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
69.48%
69.48%
69.48%
69.48%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.67%
69.67%
69.74%
69.74%
69.74%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
4.52%
4.46%
4.32%
3.94%
4.17%
3.94%
3.96%
4.05%
4.24%
4.25%
DIIs
10.92%
11.17%
11.36%
11.56%
11.69%
12.06%
12.43%
12.76%
13.31%
13.40%
13.93%
14.50%
15.38%
15.47%
16.05%
16.06%
16.43%
16.46%
16.30%
16.17%
16.18%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
10.99%
10.78%
11.43%
9.57%
9.22%
8.91%
9.12%
9.21%
9.08%
8.98%
8.24%
8.00%
7.41%
7.48%
7.36%
7.26%
7.07%
7.01%
6.93%
6.87%
6.86%
Others
8.61%
8.57%
7.73%
9.39%
9.47%
9.41%
8.84%
8.42%
8.00%
8.01%
8.22%
3.37%
3.14%
3.13%
3.04%
2.90%
2.88%
2.89%
2.99%
2.98%
2.96%
No. of Shareholders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969
87,000
86,432

Documents

Frequently Asked Questions about Alembic Pharmaceuticals Ltd

What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Where is Alembic Pharmaceuticals Ltd (APLLTD) listed?
Alembic Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: APLLTD and BSE: 533573. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a market capitalisation of approximately ₹15377.13 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Alembic Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 22.48. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Alembic Pharmaceuticals Ltd?
Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.8 and a high of ₹1,107.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Alembic Pharmaceuticals Ltd pay dividends?
Yes, Alembic Pharmaceuticals Ltd has a dividend yield of 1.41%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a Return on Equity (ROE) of 12.78%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Alembic Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Alembic Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

Website alembic-india.com
CEO Mr. Chirayu Ramanbhai Amin
Employees 16,571
Listed 2011-09-20
Face Value ₹ 2
Issued Size 19,65,63,124

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List